According to Dr. Ira L. Goldknopf, Chief Scientific Officer and Head of the Scientific Team at Power3, "By utilizing our very sensitive and reproducible proteomic methods with definitive patient samples, we discovered a series of proteins whose concentrations in the bone marrow aspirate samples, taken from Chronic Myelogenous Leukemia (CML) patients before treatment, demonstrated a consistent correlation with whether the patients subsequently responded to the treatment with a particular drug. The identities of these proteins, which apparently detect the presence of drug resistant cancer cells prior to treatment, also indicate a potential to design drugs to kill both sensitive and resistant cancer cells."
 


New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com

Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com

CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com

Post Message: [email protected]
Subscribe:  [EMAIL PROTECTED]
Unsubscribe:  [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED] 
CML Group Web Site http://groups.yahoo.com/group/CML




YAHOO! GROUPS LINKS




Reply via email to